^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DCBY02
i
Other names: DCBY02
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
DynamiCure Biotech
Drug class:
CD93 inhibitor
Related drugs:
almost2years
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=5, Terminated, DynamiCure Biotechnology | N=108 --> 5 | Trial completion date: Oct 2024 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2024 --> Feb 2024; Review of Data, and our other compound is a better option
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
DCBY02
almost2years
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=108, Active, not recruiting, DynamiCure Biotechnology | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
PD-L1 (Programmed death ligand 1)
|
DCBY02
almost3years
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=96, Recruiting, DynamiCure Biotechnology | N=192 --> 96
Enrollment change • Metastases
|
PD-L1 (Programmed death ligand 1)
|
DCBY02
almost3years
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=192, Recruiting, DynamiCure Biotechnology | N=96 --> 192
Enrollment change • Metastases
|
PD-L1 (Programmed death ligand 1)
|
DCBY02
3years
DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=96, Recruiting, DynamiCure Biotechnology | Not yet recruiting --> Recruiting
Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
DCBY02 • DCSZ11
Share via
